IDC AND JIJA PARTNER IN $24.1MILLION VACCINE MANUFACTURING PROJECT AT LS-MFEZ
By Alain Kabinda
The Industrial Development Corporation (IDC), in partnership with China's Jijia (Beijing) International Medical Technology Co. Ltd, has embarked on a US$24.1 million investment in vaccine manufacturing, marking a major step towards building Zambia's pharmaceutical industry and reducing dependence on imported vaccines.
The project, operating under ZAMVAX, is being established at the Lusaka South Multi-Facility Economic Zone (LS-MFEZ) and is designed to produce up to 20 million doses of oral cholera vaccine annually during its first phase.
The investment is expected to strengthen domestic vaccine supply, promote technology transfer, create skilled employment and position Zambia to participate in the growing African vaccine manufacturing market.
The groundbreaking ceremony was officiated by Health Minister Professor Roma Chilengi, who said the facility represented an important investment in both public health security and the country's industrial development ambitions.
Speaking during the ceremony Professor Chilengi said Zambia's experience with recurrent cholera outbreaks and the COVID-19 pandemic had demonstrated the economic and social consequences of relying heavily on external vaccine supplies.
He said local vaccine manufacturing would strengthen the country's ability to respond to public health emergencies while protecting household incomes, business operations and economic productivity.
Prof. Chilengi The Minister said the project would initially focus on producing OraVacs oral cholera vaccine to support national efforts to prevent and control cholera.
He said a dependable supply of oral cholera vaccine would complement other interventions, including access to safe water, improved sanitation, disease surveillance and timely medical care.
ZAMVAX is structured as a joint venture in which IDC holds a 60 per cent stake, while Jijia owns 40 per cent, combining Zambian majority ownership with international technical expertise and technology transfer.
Professor Chilengi said the partnership followed the signing of a memorandum of understanding between the two institutions in October 2024, which was witnessed by President Hakainde Hichilema.
He acknowledged the President's advocacy for cholera control and commercially viable vaccine manufacturing in Africa, adding that the partners should develop a sustainable operation capable of serving Zambia and other countries.
The first phase will involve solid oral Fill-and-Finish operations for OraVacs, using imported bulk vaccine material for local processing, packaging and quality control.
As investment, technical capacity and the workforce develop, ZAMVAX intends to progressively undertake more stages of production locally, with the longer-term ambition of achieving end-to-end manufacturing for selected vaccines.
The partnership will also assess opportunities to manufacture additional vaccines based on public health priorities, including products under the Expanded Programme on Immunisation.
Potential areas include human papillomavirus (HPV) and malaria vaccines, while the broader partnership also provides scope for animal vaccine production, subject to technical and commercial assessments, financing and regulatory requirements.
However, access to regional and continental markets will depend on the facility demonstrating consistent product quality and meeting the regulatory requirements of individual countries.
He further said the investment was aligned with the Government's Grow Zambia Agenda, particularly its emphasis on local manufacturing, value addition, industrialisation and employment creation.
He said the facility would create demand for specialised skills, including engineers, production personnel, technicians and quality assurance professionals.
The project was also expected to create opportunities for Zambian businesses supplying maintenance services, equipment calibration, utilities, packaging and logistics.
He encouraged local companies to develop the capacity to meet the required standards so that they could participate in the vaccine manufacturing value chain and build expertise applicable to other industries.
The development of local manufacturing capacity is also expected to strengthen linkages between the pharmaceutical industry, technical institutions and other businesses providing specialised services.
They called on universities, technical colleges, research organisations and private investors to work with ZAMVAX in developing skills and identifying products that could be manufactured locally.
Professor Chilengi said Zambia needed a pathway through which scientific research conducted locally could be transformed into products that support national immunisation programmes.
Meanwhile, Chinese Embassy Minister-Counsellor Wang Sheng said the ZAMVAX vaccine manufacturing facility would strengthen Zambia's health security while creating opportunities for industrial development and regional trade.
Mr Wang, who represented Chinese Ambassador Han Jing at the groundbreaking ceremony, said the project was a significant milestone in China-Zambia cooperation and would help reduce Zambia's dependence on imported vaccines.
He said the facility, with a designed annual production capacity of 20 million doses, would help reduce foreign currency expenditure on vaccine imports, lower procurement and transportation costs and minimise risks associated with global supply chain disruptions.
He disclosed that the latest wave of cholera recorded in Zambia from August 2026 had resulted in 2,919 suspected cases, 392 confirmed cases and 65 deaths at the time of his address.
He said local vaccine production would strengthen the country's ability to respond quickly to outbreaks by ensuring more reliable access to vaccines and reducing delays associated with international procurement and transportation.
Mr Wang said the project had strategic importance beyond Zambia because it was expected to support vaccine supply to neighbouring countries and strengthen regional cooperation in disease prevention.
He described ZAMVAX as Africa's first cholera vaccine production project and said its planned capacity could help position Zambia as a regional supplier of public health products once the facility became operational.
He said the investment would contribute to Africa's ambition of eliminating cholera by 2030 by supporting a more self-reliant and resilient public health system.
Mr Wang further said the project represented an important industrial investment that would help diversify Zambia's economy and address the gap in domestic vaccine manufacturing.
He said vaccine production would create employment opportunities while introducing advanced technology, management expertise and professional training that could develop Zambia's technical and managerial workforce.
Mr Wang reaffirmed China's commitment to strengthening health cooperation with Zambia, noting that the two countries had a longstanding partnership in the health sector.
He said China had dispatched more than 1,000 medical personnel to Zambia since 1978, including Chinese medical teams and military medical experts.
He also recalled China's support during the COVID-19 pandemic, when the Levy Mwanawasa Teaching Hospital was delivered ahead of schedule in March 2020 and subsequently designated as Lusaka's sole COVID-19 treatment hospital.
Mr Wang said China had also donated more than 100,000 doses of oral cholera vaccines to Zambia in 2025 and was expected to provide anti-HIV medicines and test kits in 2026.
He said China would continue supporting Zambia's public health system through the Ten Partnership Actions, including the Health Partnership Initiative, as part of efforts to strengthen disease prevention and control.
And speaking at the ceremony, Industrial Development Corporation Zambia (IDC) Chief Executive Officer Mr. Cornwell Muleya said the groundbreaking marked the transition of the joint-venture partnership into a practical commitment to building lasting productive capacity.
Mr. Muleya said the project would focus on technology transfer, local participation and establishing a commercially sustainable enterprise capable of supplying vaccines reliably.
He said the success of the investment would be measured not only by the infrastructure constructed but also by the vaccines produced, the skills transferred to Zambians and the communities benefiting from improved access to protection.
The project also places emphasis on regulatory compliance, with the Minister of Health acknowledging the role of the Zambia Medicines Regulatory Authority (ZAMRA) and other oversight institutions in ensuring quality-assured vaccine manufacturing.
For Zambia, the ZAMVAX investment represents an opportunity to retain more value within the domestic economy, develop specialised manufacturing skills and strengthen the country's position in Africa's pharmaceutical industry.
Its long-term commercial and public health contribution will depend on successful implementation, sustained investment, technology transfer, regulatory compliance and the ability to produce vaccines that meet the needs of both domestic and regional markets.
.jpg)
No comments:
Post a Comment